183 results found
Moreddu R, Elsherif M, Adams H, et al., 2020, Integration of paper microfluidic sensors into contact lenses for tear fluid analysis., Lab Chip
In this article, using the integration of paper microfluidics within laser-inscribed commercial contact lenses, we demonstrate the multiplexed detection of clinically relevant analytes including hydrogen ions, proteins, glucose, nitrites and l-ascorbic acid, all sampled directly from model tears. In vitro measurements involved the optimization of colorimetric assays, with readouts collected, stored and analyzed using a bespoke Tears Diagnostics smartphone application prototype. We demonstrate the potential of the device to perform discrete measurements either for medical diagnosis or disease screening in the clinic or at the point-of-care (PoC), with future applications including monitoring of ocular infections, uveitis, diabetes, keratopathies and assessing oxidative stress.
Soomro T, Shah N, Niestrata-Ortiz M, et al., 2020, Recent advances in imaging technologies for assessment of retinal diseases., Expert Review of Medical Devices, Pages: 1-14, ISSN: 1743-4440
INTRODUCTION: Retinal imaging is a key investigation in ophthalmology. New devices continue to be created to keep up with the demand for better imaging modalities in this field. This review looks to highlight current trends and the future of retinal imaging. AREAS COVERED: This review looks at the advances in topographical imaging, photoacoustic microscopy, optical coherence tomography and molecular imaging. There is future scoping on further advances in retinal imaging. EXPERT OPINION: Retinal imaging continues to develop at a rapid pace to improve diagnosis and management of patients. We will see the development of big data to gain powerful insights and new technologies such as teleophthalmology mature in the future.
Maurice J, Lett A, Skinner C, et al., Transcutaneous fluorescence spectroscopy as a tool for non-invasive monitoring of gut function – first clinical experiences, Scientific Reports, ISSN: 2045-2322
Yap TE, Cordeiro MF, 2020, Treating the whole glaucoma spectrum: A new treatment approach is required, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, ISSN: 0306-5251
Yap TE, Kelada M, de Imperial-Ollero JAM, et al., 2020, Phosphodiesterase inhibitors in glaucoma (PhIGS): a prospective OCTA study, Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ISSN: 0146-0404
Balendra SI, Shamsher E, Cordeiro MF, 2020, Trehalose is neuroprotective in in vitro models of glaucoma, Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ISSN: 0146-0404
Balendra SI, Zollet P, Casasca GCADGE, et al., 2020, Personalized approaches for the management of glaucoma, EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, ISSN: 2380-8993
Normando EM, Yap TE, Maddison J, et al., 2020, A CNN-aided method to predict glaucoma progression using DARC (Detection of Apoptosing Retinal Cells), EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 20, Pages: 737-748, ISSN: 1473-7159
Diagnosis and monitoring of psychiatric disorders rely heavily on subjective self-reports of clinical symptoms, which are complicated by the varying consistency of accounts reported by patients with an impaired mental state. Hence, more objective and quantifiable measures have been sought to provide clinicians with more robust methods to evaluate symptomology and track progression of disease in response to treatments. Owing to the shared origins of the retina and the brain, it has been suggested that changes in the retina may correlate with structural and functional changes in the brain. Vast improvements in retinal imaging, namely optical coherence tomography (OCT) and electrodiagnostic technology, have made it possible to investigate the eye at a microscopic level, allowing for the investigation of potential biomarkers in vivo. This review provides a summary of retinal biomarkers associated with schizophrenia, bipolar disorder and major depression, demonstrating how retinal biomarkers may be used to complement existing methods and provide structural markers of pathophysiological mechanisms that underpin brain dysfunction in psychiatric disorders.
Traber GL, Della Volpe-Waizel M, Maloca P, et al., 2020, New technologies for outcome measures in glaucoma: review by the European vision institute special interest focus group., Ophthalmic Research: journal for research in experimental and clinical ophthalmology, Vol: 63, Pages: 88-96, ISSN: 0030-3747
Glaucoma is the leading cause of irreversible blindness worldwide, with an increasing prevalence. The complexity of the disease has been a major challenge in moving the field forward with regard to both pathophysiological insight and treatment. In this context, discussing possible outcome measures in glaucoma trials is of utmost importance and clinical relevance. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "New Technologies for Outcome Measures in Retina and Glaucoma," addressing both functional and structural outcomes, as well as translational hot topics in glaucoma and retina research. In conjunction with the published literature, this review summarizes the meeting focusing on glaucoma.
Guo L, Davis BM, Ravindran N, et al., 2020, Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration, Scientific Reports, Vol: 10, ISSN: 2045-2322
Optic neuropathy is a major cause of irreversible blindness worldwide, and no effective treatment is currently available. Secondary degeneration is believed to be the major contributor to retinal ganglion cell (RGC) death, the endpoint of optic neuropathy. Partial optic nerve transection (pONT) is an established model of optic neuropathy. Although the mechanisms of primary and secondary degeneration have been delineated in this model, until now how this is influenced by therapy is not well-understood. In this article, we describe a clinically translatable topical, neuroprotective treatment (recombinant human nerve growth factor, rh-NGF) predominantly targeting secondary degeneration in a pONT rat model. Topical application of rh-NGF twice daily for 3 weeks significantly improves RGC survival as shown by reduced RGC apoptosis in vivo and increased RGC population in the inferior retina, which is predominantly affected in this model by secondary degeneration. Topical rh-NGF also promotes greater axonal survival and inhibits astrocyte activity in the optic nerve. Collectively, these results suggest that topical rh-NGF exhibits neuroprotective effects on retinal neurons via influencing secondary degeneration process. As topical rh-NGF is already involved in early clinical trials, this highlights its potential in multiple indications in patients, including those affected by glaucomatous optic neuropathy.
Mohamed NG, Yap TE, Almonte M, et al., 2020, Focusing on surgical and laser advances in glaucoma management, EXPERT REVIEW OF OPHTHALMOLOGY, Vol: 15, Pages: 27-41, ISSN: 1746-9899
Yetisen AK, Jiang N, Castaneda Gonzalez CM, et al., 2020, Scleral lens sensor for ocular electrolyte analysis., Advanced Materials, Vol: 32, Pages: 1-17, ISSN: 0935-9648
The quantitative analysis of tear analytes in point-of-care settings can enable early diagnosis of ocular diseases. Here, a fluorescent scleral lens sensor is developed to quantitatively measure physiological levels of pH, Na+ , K+ , Ca2+ , Mg2+ , and Zn2+ ions. Benzenedicarboxylic acid, a pH probe, displays a sensitivity of 0.12 pH units within pH 7.0-8.0. Crown ether derivatives exhibit selectivity to Na+ and K+ ions within detection ranges of 0-100 and 0-50 mmol L-1 , and selectivities of 15.6 and 8.1 mmol L-1 , respectively. A 1,2 bis(o-aminophenoxy)ethane-N,N,-N',N'-tetraacetic-acid-based probe allows Ca2+ ion sensing with 0.02-0.05 mmol L-1 sensitivity within 0.50-1.25 mmol L-1 detection range. 5-Oxazolecarboxylic acid senses Mg2+ ions, exhibiting a sensitivity of 0.10-0.44 mmol L-1 within the range of 0.5-0.8 mmol L-1 . The N-(2-methoxyphenyl)iminodiacetate Zn2+ ion sensor has a sensitivity of 1 µmol L-1 within the range of 10-20 µmol L-1 . The fluorescent sensors are subsequently multiplexed in the concavities of an engraved scleral lens. A handheld ophthalmic readout device comprising light-emitting diodes (LEDs) and bandpass filters is fabricated to excite as well as read the scleral sensor. A smartphone camera application and an user interface are developed to deliver quantitative measurements with data deconvolution. The ophthalmic system enables the assessment of dry eye severity stages and the differentiation of its subtypes.
Yap TE, Shamsher E, Guo L, et al., 2020, Ophthalmic Research Lecture 2018: DARC as a Potential Surrogate Marker, OPHTHALMIC RESEARCH, Vol: 63, Pages: 1-7, ISSN: 0030-3747
Normando EM, Cordeiro MF, 2020, Animal models in neuro ophthalmology, OCT and Imaging in Central Nervous System Diseases: The Eye as a Window to the Brain: Second Edition, Pages: 401-426, ISBN: 9783030262686
Considering the retina as an extension of the brain provides a platform from which to study diseases of the nervous system. Taking advantage of the clear optical media of the eye and ever-increasing resolution of modern imaging techniques, retinal morphology can now be visualized at a cellular level in vivo. This has provided a multitude of possible biomarkers and investigative surrogates that may be used to identify, monitor and study diseases until now limited to the brain. In many neurodegenerative conditions, early diagnosis is often very challenging due to the lack of tests with high sensitivity and specificity, but, once made, opens the door to patients accessing the correct treatment that can potentially improve functional outcomes. Using retinal biomarkers in vivo as an additional diagnostic tool may help overcome the need for invasive tests and histological specimens, and offers the opportunity to longitudinally monitor individuals over time. This review aims to summarise retinal biomarkers associated with a range of neurological conditions including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and prion diseases from a clinical perspective. By comparing their similarities and differences according to primary pathological processes, we hope to show how retinal correlates can aid clinical decisions, and accelerate the study of this rapidly developing area of research.
Mercuri S, Davis B, Yap T, et al., 2019, Longitudinal morphological assessment of macular changes in glaucoma, Publisher: WILEY, ISSN: 1755-375X
Walpert MJ, Normando EM, Annus T, et al., 2019, Age-related retinal thickness in Down's syndrome: A high-risk population for dementia., Alzheimers Dement (Amst), Vol: 11, Pages: 744-751, ISSN: 2352-8729
Introduction: People with Down's syndrome (DS) have a high prevalence of early-onset Alzheimer's disease. Early markers of Alzheimer's disease pathology identifiable before clinical change are needed for the evaluation of preventative treatments. The retina, an extension of the brain, may provide a noninvasive imaging site. Methods: Forty-nine adults with DS and 36 age-matched controls completed retinal nerve fibre layer (RNFL) assessments using optical coherence tomography. RNFL thickness was analyzed in relation to cognitive status and age and previously acquired cortical thickness and cerebral amyloid β binding data in a subgroup. Results: RNFL thickness was greater in the DS group and did not show age-related thinning. RNFL correlated positively with cognitive scores and cortical thickness and was reduced in participants with positive cerebral amyloid β binding. Discussion: Increased RNFL in adults with DS may represent early Alzheimer's disease-related changes. Thinning was present in those with cerebral amyloid β binding, independent of age.
Blumenthal EZ, Cordeiro MF, Shmetterer L, et al., 2019, ISOPT Clinical Hot Topic Panel Discussion on Glaucoma., J Ocul Pharmacol Ther, Vol: 35, Pages: 441-446
As part of the 14th International Symposium on Ocular and Pharmacological Therapeutics, a unique panel was gathered to discuss two cardinal questions related to the treatment of glaucoma, peeking into the future: (1) What shape and form will glaucoma medical treatment have five and fifteen years from today, and (2) Will personalized medicine be commonly used five years from now. For each of the questions, we assigned an "optimist" and "pessimist" who provided the assigned point of view, for a total of 4 discussants, the authors of this panel discussion.
Normando EM, Davis BM, Yap TE, et al., 2019, Objective Assessment of Progressive Macular Changes in Glaucoma, Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ISSN: 0146-0404
Davis BM, Tian K, Pahlitzsch M, et al., 2019, Corrigendum to “Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension” [Mitochondrion 36 (2017) 114–123], Mitochondrion, Vol: 47, Pages: 330-330, ISSN: 1567-7249
Shamsher E, Davis BM, Yap TE, et al., 2019, Neuroprotection in glaucoma: old concepts, new ideas, EXPERT REVIEW OF OPHTHALMOLOGY, Vol: 14, Pages: 101-113, ISSN: 1746-9899
Arranz-Romera A, Davis BM, Bravo-Osuna I, et al., 2019, Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma, JOURNAL OF CONTROLLED RELEASE, Vol: 297, Pages: 26-38, ISSN: 0168-3659
D'Esposito F, Miodragovic S, Normando EM, et al., 2018, The 100 000 genomes project and the Western Eye Hospital experience, Publisher: WILEY, Pages: 28-28, ISSN: 1755-375X
Davis B, Guo L, Pahlitzsch M, et al., 2018, RGC cell size and susceptibility to loss in rodent glaucoma models, Publisher: WILEY, Pages: 30-31, ISSN: 1755-375X
Davis B, Pahlitzsch M, Balendra S, et al., 2018, Evaluation of topical curcumin nanoparticles in of rodent glaucoma models, Publisher: WILEY, Pages: 30-30, ISSN: 1755-375X
Guo L, Normando EM, Shah PA, et al., 2018, Oculo-Visual Abnormalities in Parkinson's Disease: Possible Value as Biomarkers, MOVEMENT DISORDERS, Vol: 33, Pages: 1390-1406, ISSN: 0885-3185
Davis BM, Pahlitzsch M, Guo L, et al., 2018, Topical curcumin nanocarriers are neuroprotective in eye disease, Scientific Reports, Vol: 8, ISSN: 2045-2322
Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5dione) is a polyphenol extracted from turmeric that has long been advocated for the treatment of a variety of conditions including neurodegenerative and inflammatory disorders. Despite this promise, the clinical use of curcumin has been limited by the poor solubility and low bioavailability of this molecule. In this article, we describe a novel nanocarrier formulation comprising Pluronic-F127 stabilised D-α-Tocopherol polyethene glycol 1000 succinate nanoparticles, which were used to successfully solubilize high concentrations (4.3 mg/mL) of curcumin. Characterisation with x-ray diffraction and in vitro release assays localise curcumin to the nanocarrier interior, with each particle measuring <20 nm diameter. Curcumin-loaded nanocarriers (CN) were found to significantly protect against cobalt chloride induced hypoxia and glutamate induced toxicity in vitro, with CN treatment significantly increasing R28 cell viability. Using established glaucoma-related in vivo models of ocular hypertension (OHT) and partial optic nerve transection (pONT), topical application of CN twice-daily for three weeks significantly reduced retinal ganglion cell loss compared to controls. Collectively, these results suggest that our novel topical CN formulation has potential as an effective neuroprotective therapy in glaucoma and other eye diseases with neuronal pathology.
Cordeiro MF, 2018, DARC and Glaucoma, Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ISSN: 0146-0404
Normando EM, Blackwell C, Cordeiro MF, 2018, Effect of Topical Trehalose/Hyaluronic Acid on OCT Image Quality in Glaucoma Patients, Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ISSN: 0146-0404
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.